Q3 Earnings Forecast for STOK Issued By HC Wainwright

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Stoke Therapeutics in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.55) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.18) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.21) EPS and FY2029 earnings at $0.22 EPS.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million.

A number of other brokerages also recently commented on STOK. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Chardan Capital reiterated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $23.00.

Stoke Therapeutics Stock Down 2.2 %

Shares of STOK opened at $8.15 on Friday. Stoke Therapeutics has a 52 week low of $6.29 and a 52 week high of $17.58. The company has a market capitalization of $431.68 million, a price-to-earnings ratio of -3.88 and a beta of 0.99. The stock’s 50-day moving average price is $9.47 and its 200-day moving average price is $11.42.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares of the company’s stock, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock valued at $143,332 over the last quarter. 11.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently made changes to their positions in STOK. Toronto Dominion Bank acquired a new position in shares of Stoke Therapeutics during the fourth quarter valued at approximately $35,001,000. RTW Investments LP increased its holdings in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after purchasing an additional 471,240 shares during the last quarter. Norges Bank acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $3,472,000. Tang Capital Management LLC acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $3,309,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $3,218,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.